User profiles for Anne-Sophie Hamy
 | Anne-Sophie Hamy-PetitInstitut Curie, Paris Verified email at curie.fr Cited by 2814 |
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
…, J Lehmann-Che, A de Roquancourt, AS Hamy… - European journal of …, 2011 - Springer
Purpose The aim of this study was to determine the impact of the main clinicopathological
and biological prognostic factors of breast cancer on 18 F-fluorodeoxyglucose (FDG) uptake. …
and biological prognostic factors of breast cancer on 18 F-fluorodeoxyglucose (FDG) uptake. …
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses
Increasing evidence implicates the tumor microbiota as a factor that can influence cancer
progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics …
progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics …
Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer
Background This study prospectively evaluated the yield of fluorodeoxyglucose positron
emission tomography/computed tomography ( 18 FDG-PET-CT) in patients with clinical stages II …
emission tomography/computed tomography ( 18 FDG-PET-CT) in patients with clinical stages II …
Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations
PURPOSE Young women with germline BRCA mutations have unique reproductive challenges.
Pregnancy after breast cancer does not increase the risk of recurrence; however, very …
Pregnancy after breast cancer does not increase the risk of recurrence; however, very …
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
J Lehmann-Che, AS Hamy, R Porcher… - Breast Cancer …, 2013 - Springer
Introduction Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast
cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 …
cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 …
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL
…, L Lacroix, F Lemonnier, AS Hamy… - Blood, The Journal …, 2020 - ashpublications.org
The oncogenic events involved in breast implant–associated anaplastic large cell lymphoma
(BI-ALCL) remain elusive. To clarify this point, we have characterized the genomic …
(BI-ALCL) remain elusive. To clarify this point, we have characterized the genomic …
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study
…, M Espié, L Vercellino, AS Hamy… - Journal of Nuclear …, 2011 - Soc Nuclear Med
The purpose of this study was to prospectively evaluate the role of 18 F-FDG PET/CT in
patients with stage IIA, IIB, or IIIA breast cancer. Methods: During 56 mo, 131 consecutive …
patients with stage IIA, IIB, or IIIA breast cancer. Methods: During 56 mo, 131 consecutive …
Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic …
Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast
tumors. This prospective study investigated whether early changes in 18 F-FDG tumor uptake …
tumors. This prospective study investigated whether early changes in 18 F-FDG tumor uptake …
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant …
AS Hamy, L Darrigues, E Laas, D De Croze, L Topciu… - PloS one, 2020 - journals.plos.org
Introduction The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant
chemotherapy (NAC). Its predictive value has not been validated on large cohorts with …
chemotherapy (NAC). Its predictive value has not been validated on large cohorts with …
